Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed/refractory multiple myeloma (RRMM): update of the phase 1/2 EVOLVE study (NCT03430011).
Sham Mailankody(Memorial Sloan Kettering Cancer Center), Sandy W. Wong(University of California, San Francisco), Siddhartha Ganguly(University of Kansas Medical Center), Myo Htut(City Of Hope National Medical Center), David S. Siegel(Hackensack Meridian Health), Mariana Cota(Bristol-Myers Squibb (United States)), Andrzej Jakubowiak(University of Michigan), Jonathan L. Kaufman(Emory University), Thomas Doerr(Bristol-Myers Squibb (United States)), Kelvin Lee(Roswell Park Comprehensive Cancer Center), Todd DeVries, William Bensinger(Fred Hutch Cancer Center), Luciano J. Costa(Université Paris Cité)
Cited by 122
Related Papers
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
Methotrexate and Cyclosporine Compared with Cyclosporine Alone for Prophylaxis of Acute Graft versus Host Disease after Marrow Transplantation for Leukemia
|New England Journal of Medicine|1986|1.5k
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
|Leukemia|2011|721
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719